Ketamine sublingual - iX Biopharma

Drug Profile

Ketamine sublingual - iX Biopharma

Alternative Names: Ketamine wafer - iX Biopharma; Wafermine

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator iX Biopharma
  • Class Analgesics; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Dental pain; Pain

Most Recent Events

  • 25 Jan 2017 iX Biopharma plans a bioavailability clinical trial in Healthy volunteers in Australia (Sublingual) (ACTRN12617000140358p)
  • 01 Aug 2016 iX Biopharma completes a phase II bioavailability trial in Healthy volunteers in Australia (Sublingual) (NCT02857361)
  • 01 Jul 2016 iX Biopharma initiates a phase II bioavailability trial in Healthy volunteers in Australia (Sublingual) (NCT02857361)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top